Cargando…
Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome
AIMS: Patients with idiopathic pulmonary fibrosis (IPF) receiving antifibrotic medication and patients with non-IPF fibrosing lung disease often demonstrate rates of annualised forced vital capacity (FVC) decline within the range of measurement variation (5.0%–9.9%). We examined whether change in vi...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402558/ https://www.ncbi.nlm.nih.gov/pubmed/32345689 http://dx.doi.org/10.1136/thoraxjnl-2019-213865 |
_version_ | 1783566782542381056 |
---|---|
author | Jacob, Joseph Aksman, Leon Mogulkoc, Nesrin Procter, Alex J Gholipour, Bahareh Cross, Gary Barnett, Joseph Brereton, Christopher J Jones, Mark G van Moorsel, Coline H van Es, Wouter van Beek, Frouke Veltkamp, Marcel Desai, Sujal R Judge, Eoin Burd, Teresa Kokosi, Maria Savas, Recep Bayraktaroglu, Selen Altmann, Andre Wells, Athol U |
author_facet | Jacob, Joseph Aksman, Leon Mogulkoc, Nesrin Procter, Alex J Gholipour, Bahareh Cross, Gary Barnett, Joseph Brereton, Christopher J Jones, Mark G van Moorsel, Coline H van Es, Wouter van Beek, Frouke Veltkamp, Marcel Desai, Sujal R Judge, Eoin Burd, Teresa Kokosi, Maria Savas, Recep Bayraktaroglu, Selen Altmann, Andre Wells, Athol U |
author_sort | Jacob, Joseph |
collection | PubMed |
description | AIMS: Patients with idiopathic pulmonary fibrosis (IPF) receiving antifibrotic medication and patients with non-IPF fibrosing lung disease often demonstrate rates of annualised forced vital capacity (FVC) decline within the range of measurement variation (5.0%–9.9%). We examined whether change in visual CT variables could help confirm whether marginal FVC declines represented genuine clinical deterioration rather than measurement noise. METHODS: In two IPF cohorts (cohort 1: n=103, cohort 2: n=108), separate pairs of radiologists scored paired volumetric CTs (acquired between 6 and 24 months from baseline). Change in interstitial lung disease, honeycombing, reticulation, ground-glass opacity extents and traction bronchiectasis severity was evaluated using a 5-point scale, with mortality prediction analysed using univariable and multivariable Cox regression analyses. Both IPF populations were then combined to determine whether change in CT variables could predict mortality in patients with marginal FVC declines. RESULTS: On univariate analysis, change in all CT variables except ground-glass opacity predicted mortality in both cohorts. On multivariate analysis adjusted for patient age, gender, antifibrotic use and baseline disease severity (diffusing capacity for carbon monoxide), change in traction bronchiectasis severity predicted mortality independent of FVC decline. Change in traction bronchiectasis severity demonstrated good interobserver agreement among both scorer pairs. Across all study patients with marginal FVC declines, change in traction bronchiectasis severity independently predicted mortality and identified more patients with deterioration than change in honeycombing extent. CONCLUSIONS: Change in traction bronchiectasis severity is a measure of disease progression that could be used to help resolve the clinical importance of marginal FVC declines. |
format | Online Article Text |
id | pubmed-7402558 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-74025582020-08-17 Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome Jacob, Joseph Aksman, Leon Mogulkoc, Nesrin Procter, Alex J Gholipour, Bahareh Cross, Gary Barnett, Joseph Brereton, Christopher J Jones, Mark G van Moorsel, Coline H van Es, Wouter van Beek, Frouke Veltkamp, Marcel Desai, Sujal R Judge, Eoin Burd, Teresa Kokosi, Maria Savas, Recep Bayraktaroglu, Selen Altmann, Andre Wells, Athol U Thorax Interstitial Lung Disease AIMS: Patients with idiopathic pulmonary fibrosis (IPF) receiving antifibrotic medication and patients with non-IPF fibrosing lung disease often demonstrate rates of annualised forced vital capacity (FVC) decline within the range of measurement variation (5.0%–9.9%). We examined whether change in visual CT variables could help confirm whether marginal FVC declines represented genuine clinical deterioration rather than measurement noise. METHODS: In two IPF cohorts (cohort 1: n=103, cohort 2: n=108), separate pairs of radiologists scored paired volumetric CTs (acquired between 6 and 24 months from baseline). Change in interstitial lung disease, honeycombing, reticulation, ground-glass opacity extents and traction bronchiectasis severity was evaluated using a 5-point scale, with mortality prediction analysed using univariable and multivariable Cox regression analyses. Both IPF populations were then combined to determine whether change in CT variables could predict mortality in patients with marginal FVC declines. RESULTS: On univariate analysis, change in all CT variables except ground-glass opacity predicted mortality in both cohorts. On multivariate analysis adjusted for patient age, gender, antifibrotic use and baseline disease severity (diffusing capacity for carbon monoxide), change in traction bronchiectasis severity predicted mortality independent of FVC decline. Change in traction bronchiectasis severity demonstrated good interobserver agreement among both scorer pairs. Across all study patients with marginal FVC declines, change in traction bronchiectasis severity independently predicted mortality and identified more patients with deterioration than change in honeycombing extent. CONCLUSIONS: Change in traction bronchiectasis severity is a measure of disease progression that could be used to help resolve the clinical importance of marginal FVC declines. BMJ Publishing Group 2020-08 2020-04-28 /pmc/articles/PMC7402558/ /pubmed/32345689 http://dx.doi.org/10.1136/thoraxjnl-2019-213865 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Interstitial Lung Disease Jacob, Joseph Aksman, Leon Mogulkoc, Nesrin Procter, Alex J Gholipour, Bahareh Cross, Gary Barnett, Joseph Brereton, Christopher J Jones, Mark G van Moorsel, Coline H van Es, Wouter van Beek, Frouke Veltkamp, Marcel Desai, Sujal R Judge, Eoin Burd, Teresa Kokosi, Maria Savas, Recep Bayraktaroglu, Selen Altmann, Andre Wells, Athol U Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome |
title | Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome |
title_full | Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome |
title_fullStr | Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome |
title_full_unstemmed | Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome |
title_short | Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome |
title_sort | serial ct analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome |
topic | Interstitial Lung Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402558/ https://www.ncbi.nlm.nih.gov/pubmed/32345689 http://dx.doi.org/10.1136/thoraxjnl-2019-213865 |
work_keys_str_mv | AT jacobjoseph serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome AT aksmanleon serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome AT mogulkocnesrin serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome AT procteralexj serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome AT gholipourbahareh serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome AT crossgary serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome AT barnettjoseph serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome AT breretonchristopherj serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome AT jonesmarkg serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome AT vanmoorselcolineh serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome AT vaneswouter serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome AT vanbeekfrouke serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome AT veltkampmarcel serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome AT desaisujalr serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome AT judgeeoin serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome AT burdteresa serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome AT kokosimaria serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome AT savasrecep serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome AT bayraktarogluselen serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome AT altmannandre serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome AT wellsatholu serialctanalysisinidiopathicpulmonaryfibrosiscomparisonofvisualfeaturesthatdeterminepatientoutcome |